|
Transplantation
|
Patient 1
|
Patient 2
|
Patient 3
|
Patient 4
|
|---|
|
1st
|
2nd
|
1st
|
2nd
|
1st
|
2nd
|
1st
|
2nd
|
|---|
|
Cell doses (× 106 cells/kg)
|
1.0
|
1.0
|
1.0
|
1.0
|
1.0
|
1.0
|
1.0
|
1.0
|
|
Cell viability (%)
|
97
|
97
|
96
|
98
|
98
|
98
|
97
|
89
|
|
CD73 (%)
|
97.9
|
98.5
|
98.5
|
98.3
|
98.4
|
99.63
|
99.5
|
99.6
|
|
CD90 (%)
|
100
|
100
|
100
|
100
|
100
|
99.7
|
100
|
99.9
|
|
CD105 (%)
|
100
|
100
|
100
|
100
|
100
|
100
|
100
|
100
|
|
Negative markers* (%)
|
0.9
|
0.3
|
0.3
|
0.7
|
0.1
|
0.1
|
0.0
|
0.0
|
|
Microorganism and fungal tests
|
Negative
|
|
Mycoplasma
|
Negative
|
|
Endotoxin (EU/ml)
|
< 0.1
|
< 0.05
|
< 0.1
|
< 0.1
|
0.073
|
< 0.05
|
< 0.05
|
< 0.05
|
|
Karyotyping
|
46, XY, 16qh +
|
|
CFU assay (CFU per 1000 cells)
|
519 ± 80
|
|
Adipogenesis
|
Pass
|
|
Chondrogenesis
|
Pass
|
|
Osteogenesis
|
Pass
|
- * CD11b, CD19, CD34, CD45, and HLR-DR
